Dr Walid Khaled
Dr Walid Khaled is pleased to consider applications from prospective PhD students.
My laboratory focuses on the triple-negative breast cancer (TNBC) subtype of breast cancer. TNBC is an aggressive form of breast cancer, which accounts for 15-20% of all the breast cancer cases and generally has a higher possibility of spreading to other tissues and lower rates of survival. TNBC is named after the histological characteristics of the tumour. Breast tumours are routinely tested for the presence of three key markers: Estrogen, Progesterone and Her2 receptors. TNBC tumours are negative for all three markers. As these three markers are targets for very successful breast cancer therapies, their absence in TNBC patients means that they have limited therapeutic options other than aggressive chemotherapy. Therefore, identifying genes that are responsible for the development of TNBC/BLBC is essential for the development of targeted therapies. In our laboratory we use a combination of mouse genetics and cancer genomics to identify novel TNBC genes and test their feasibility as drug targets.
Symplectic Elements feed provided by Research Information, University of Cambridge